These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29484273)

  • 21. Economic and quality of life evaluation of different modalities of immunoglobulin therapy in chronic dysimmune neuropathies.
    Cocito D; Serra G; Paolasso I; Barilà DA; Lopiano L; Cattel L
    J Peripher Nerv Syst; 2012 Dec; 17(4):426-8. PubMed ID: 23279347
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy of intravenous immunoglobulin in multifocal motor neuropathy.
    Leger JM; Vargas S; Lievens I
    Ann N Y Acad Sci; 2007 Sep; 1110():248-55. PubMed ID: 17911439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: treatment update.
    Nobile-Orazio E; Gallia F; Tuccillo F; Terenghi F
    Curr Opin Neurol; 2010 Oct; 23(5):519-23. PubMed ID: 20689427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy.
    Rajabally YA; Afzal S
    J Neurol; 2019 Feb; 266(2):461-467. PubMed ID: 30556098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis.
    Lazzaro C; Lopiano L; Cocito D
    Neurol Sci; 2014 Jul; 35(7):1023-34. PubMed ID: 24469345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dramatic clinical response to ultra-high dose IVIg in otherwise treatment resistant inflammatory neuropathies.
    Kapoor M; Reilly MM; Manji H; Lunn MP; Aisling S ; Carr
    Int J Neurosci; 2022 Apr; 132(4):352-361. PubMed ID: 32842835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Intravenous immunoglobulin-induced eczematous eruption in autoimmune neuromuscular diseases].
    Hatake S; Shimizu F; Honda M; Takahashi S; Koga M; Kimura K; Kanda T
    Rinsho Shinkeigaku; 2022 Apr; 62(4):267-271. PubMed ID: 35354723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of IVIg in autoimmune neuropathies: the latest evidence.
    Hughes R
    J Neurol; 2008 Jul; 255 Suppl 3():7-11. PubMed ID: 18685920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy.
    Guptill JT; Bromberg MB; Zhu L; Sharma BK; Thompson AR; Krueger A; Sanders DB
    Muscle Nerve; 2014 Jul; 50(1):47-51. PubMed ID: 24639235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on therapy of chronic immune-mediated neuropathies.
    Briani C; Cocito D; Campagnolo M; Doneddu PE; Nobile-Orazio E
    Neurol Sci; 2022 Dec; 43(Suppl 2):605-614. PubMed ID: 33452933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.
    Gorson KC; Natarajan N; Ropper AH; Weinstein R
    Muscle Nerve; 2007 Jan; 35(1):66-9. PubMed ID: 16967492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
    Markvardsen LH; Christiansen I; Jakobsen J
    Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.
    Dyer WB; Tan JC; Day T; Kiers L; Kiernan MC; Yiannikas C; Reddel S; Ng K; Mondy P; Dennington PM; Dean MM; Trist HM; Dos Remedios C; Hogarth PM; Vucic S; Irving DO
    Brain Behav; 2016 Oct; 6(10):e00516. PubMed ID: 27781132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
    Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
    J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany.
    Mengel D; Fraune L; Sommer N; Stettner M; Reese JP; Dams J; Glynn RJ; Balzer-Geldsetzer M; Dodel R; Tackenberg B
    Muscle Nerve; 2018 Nov; 58(5):681-687. PubMed ID: 30073683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).
    Bus SRM; Zambreanu L; Abbas A; Rajabally YA; Hadden RDM; de Haan RJ; de Borgie CAJM; Lunn MP; van Schaik IN; Eftimov F;
    Trials; 2021 Feb; 22(1):155. PubMed ID: 33608058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of inflammatory and paraproteinemic neuropathies.
    Monaco S; Turri E; Zanusso G; Maistrello B
    Curr Drug Targets Immune Endocr Metabol Disord; 2004 Jun; 4(2):141-8. PubMed ID: 15180454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study.
    Piscitelli E; Massa M; De Martino BM; Serio CS; Guglielmi G; Colacicco G; Tuccillo F; Habetswallner F
    Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e115-e119. PubMed ID: 33122403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term treatment of Lewis-Sumner syndrome with subcutaneous immunoglobulin infusions.
    Bayas A; Gold R; Naumann M
    J Neurol Sci; 2013 Jan; 324(1-2):53-6. PubMed ID: 23095259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies.
    Dalakas MC
    J Peripher Nerv Syst; 2012 May; 17 Suppl 2():34-9. PubMed ID: 22548621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.